A useful method to evaluate bone resorption inhibitors, using osteoclast-like multinucleated cells.
Since excessive bone resorption in postmenopausal osteoporosis is a pathological manifestation of the disease, it is important to control bone resorption activity of osteoclasts as a means of controlling the disease. To screen bone resorption inhibitors, a simple and quantitative method to assay bone resorption is needed. However, it has been difficult to prepare a lot of osteoclasts required for the screening of many compounds in vitro. We used the method for the preparation of mouse osteoclast-like multinucleated cells in vitro and developed a useful method in which osteoclast-like multinucleated cells were placed on dentin slices and the calcium released from dentin into the culture medium was measured. Under the optimal conditions, the increase of the calcium concentration caused by bone resorption activity of the osteoclast-like cells was significant and inhibited by calcitonin in a dose-dependent manner. We also examined the inhibitory effect of calcitonin on the pit area caused by bone resorption and found that the decrease of the calcium released from dentin was correlated with that of the pit area. Furthermore, several known bone resorption inhibitors such as bisphosphonate, bafilomycin A1, and herbimycin A showed inhibitory effects on the calcium release from dentin slices. Thus, this simple method provides us a useful screening system to find bone resorption inhibitors with novel mechanisms.
Sugawara
K
K
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Japan.
Hamada
M
M
Hosoi
S
S
Tamaoki
T
T
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016227:Benzoquinones; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D002116:Calcitonin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism / Q000502:physiology; D002478:Cells, Cultured; D003470:Culture Media; D003804:Dentin / Q000378:metabolism; D004164:Diphosphonates / Q000494:pharmacology; D004353:Drug Evaluation, Preclinical / Q000379:methods; D015726:Giant Cells / Q000187:drug effects / Q000378:metabolism; D047029:Lactams, Macrocyclic; D018942:Macrolides; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives
D000900:Anti-Bacterial Agents; D016227:Benzoquinones; D003470:Culture Media; D004164:Diphosphonates; D047029:Lactams, Macrocyclic; D018942:Macrolides; D011809:Quinones; D017828:Rifabutin; C020754:herbimycin; C040929:bafilomycin A1; D002116:Calcitonin; D002118:Calcium